Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Zifanocycline in Healthy Subjects
NCT05507463Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zifanocycline in community-acquired bacterial pneumonia (CAP), acute bacterial skin and skin structure infections (ABSSSI) and Intra-abdominal infection (IAI) (3 arms), sponsored by KBP Biosciences. Primary endpoint: Number of participants with adverse events. Started Aug 2022; status: completed.
02
Drugs
zifanocycline
03
Conditions
community-acquired bacterial pneumonia (CAP)acute bacterial skin and skin structure infections (ABSSSI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT05507463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507463.